PharmaEngine, Inc. (TPEX:4162)
Taiwan · Delayed Price · Currency is TWD 52.90
-1.70 (-3.11%)
Nov 6, 2026, 1:30 PM CST
PharmaEngine Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,601 | 10,115 | 12,974 | 15,158 | 17,961 | 10,207 | |
Market Cap Growth | -25.91% | -22.04% | -14.41% | -15.60% | 75.96% | 21.08% |
Enterprise Value | 2,567 | 5,527 | 9,241 | 11,619 | 14,348 | 6,496 |
Last Close Price | 52.90 | 68.13 | 80.67 | 92.59 | 107.01 | 60.23 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.11 | 26.09 | 7.41 | 55.19 | 56.34 | 23.96 |
Forward PE | - | 26.00 | 10.91 | 42.71 | 150.60 | 28.38 |
PS Ratio | 7.41 | 11.10 | 5.14 | 19.75 | 27.45 | 15.59 |
PB Ratio | 1.55 | 2.05 | 2.40 | 3.92 | 4.64 | 2.59 |
P/TBV Ratio | 1.55 | 2.05 | 2.40 | 3.93 | 4.64 | 2.59 |
P/FCF Ratio | 14.07 | 5.86 | 28.46 | 59.08 | 90.45 | 10.98 |
P/OCF Ratio | 14.06 | 5.86 | 28.41 | 58.99 | 88.91 | 10.98 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.50 | 6.06 | 3.66 | 15.14 | 21.93 | 9.92 |
EV/EBITDA Ratio | 5.18 | 12.94 | 4.50 | 41.71 | 50.62 | 17.88 |
EV/EBIT Ratio | 5.29 | 12.99 | 4.50 | 41.92 | 50.75 | 17.91 |
EV/FCF Ratio | 4.75 | 3.20 | 20.27 | 45.29 | 72.26 | 6.99 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.08 | 0.10 | 0.00 | 0.05 | 0.08 | 0.02 |
Debt / FCF Ratio | 0.07 | 0.02 | 0.02 | 0.06 | 0.11 | 0.01 |
Net Debt / Equity Ratio | -1.02 | -0.95 | -0.71 | -0.93 | -0.94 | -0.97 |
Net Debt / EBITDA Ratio | -10.34 | -10.94 | -1.87 | -12.97 | -12.84 | -10.47 |
Net Debt / FCF Ratio | -9.32 | -2.71 | -8.45 | -14.08 | -18.33 | -4.09 |
Asset Turnover | 0.18 | 0.17 | 0.52 | 0.19 | 0.16 | 0.16 |
Inventory Turnover | 1.71 | 1.52 | 2.16 | 1.94 | 2.50 | 2.46 |
Quick Ratio | 11.11 | 26.90 | 13.07 | 46.50 | 49.34 | 45.57 |
Current Ratio | 11.21 | 27.17 | 13.15 | 46.78 | 49.86 | 45.71 |
Return on Equity (ROE) | 11.26% | 7.51% | 37.81% | 7.10% | 8.16% | 10.72% |
Return on Assets (ROA) | 5.44% | 4.84% | 26.18% | 4.37% | 4.42% | 5.51% |
Return on Invested Capital (ROIC) | - | 36.04% | 185.11% | 93.31% | 98.51% | - |
Return on Capital Employed (ROCE) | 9.80% | 8.60% | 38.00% | 7.20% | 7.30% | 9.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.09% | 3.83% | 13.50% | 1.81% | 1.77% | 4.17% |
FCF Yield | 7.11% | 17.07% | 3.51% | 1.69% | 1.11% | 9.11% |
Dividend Yield | 3.78% | 2.84% | 6.64% | 1.42% | 1.60% | 3.80% |
Payout Ratio | 159.97% | 222.35% | 12.30% | 104.57% | 121.62% | 85.44% |
Buyback Yield / Dilution | 0.05% | -0.01% | -0.13% | -0.03% | 0.72% | 0.80% |
Total Shareholder Return | 3.83% | 2.83% | 6.51% | 1.39% | 2.32% | 4.59% |